⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588131 | 1.00 | — | — | |
| SCHEMBL2603683 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL18228312 | 0.98 | GNAI3 (0.43) | — | |
| Hydrochloric Acid SCHEMBL20186917 | 0.98 | GNAI3 (0.43) | — | |
| Hydrochloric Acid SCHEMBL26086469 | 0.98 | GNAI3 (0.43) | — | |
| Trifluoroacetic Acid SCHEMBL22264626 | 0.87 | DPP7 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL22264680 | 0.87 | DPP7 (0.42) | — | |
| SCHEMBL1226756 | 0.87 | HTR2A (0.40) | — | |
| SCHEMBL1159240 | 0.87 | HTR2A (0.40) | — | |
| SCHEMBL1159242 | 0.87 | HTR2A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394297-B2 | Amides as pim inhibitors | AMGEN INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20150329538-A1 | AMIDES AS PIM INHIBITORS | AMGEN INC. (US) | 2015-11-19 | — | — | US | claimed |
| EP-2571881-A1 | PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | claimed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | claimed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | claimed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4402138-B1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-08-27 | — | — | EP | disclosed |
| EP-1651635-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| EP-1590359-A2 | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS | CV Therapeutics Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-20040198691-A1 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004069185-A2 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | CV THERAPEUTICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |